FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046457130> ?p ?o ?g. }

• W3046457130 endingPage "e279" @default.
• W3046457130 startingPage "e275" @default.
• W3046457130 abstract "ABSTRACT Cytomegalovirus (CMV) reactivation remains one of the main infectious complications following hematopoietic stem cell transplantation (HSCT). In this study, we explored the role of anti-CMV antibody titers in HSCT from alternative donors and to compare the risk of CMV reactivation between posttransplant cyclophosphamide-based haploidentical HSCT and antithymocyte globulin-based unrelated donor (URD) HSCT. We included 98 CMV-positive patients, 30 undergoing haploidentical HSCT and 68 undergoing URD HSCT. The majority of patients had a malignant disease (84%), received a myeloablative conditioning regimen (78%), and received a bone marrow graft (90%). The median pretransplantation anti-CMV IgG level was 109 U/mL. With median follow-up of 2.2 years, a total of 72 CMV reactivations occurred in 50 patients. There was no difference in CMV reactivation pattern between haploidentical HSCT recipients and URD HSCT recipients. In multivariable analysis until the first event, the incidence of CMV reactivation was higher in patients with anti-CMV IgG levels >100 U/mL (hazard ratio [HR], 2.38; P = .005) and in patients diagnosed with grade II-IV acute graft-versus-host disease (GVHD) (HR, 10.8; P = .003) after day +50 and lower in patients who received higher doses of CD34 cells (HR, .44; P = .006). In multivariable analysis for recurring events, the incidence of CMV reactivation was higher in patients receiving reduced-intensity conditioning (HR, 1.69: P = .04) and in patients with acute GVHD (HR, 1.88; P = .02), and lower in those who received higher doses of CD34 cells (HR, .55; P = .01). In summary, we have shown that pretransplantation anti-CMV IgG titers are correlated with CMV reactivation risk. More studies are needed to assess how this information can be incorporated in HSCT. The use of high-dose cellular grafts, a modifiable risk factor, also protects against CMV reactivation." @default.
• W3046457130 created "2020-08-07" @default.
• W3046457130 creator A5003501680 @default.
• W3046457130 creator A5015706959 @default.
• W3046457130 creator A5016144976 @default.
• W3046457130 creator A5053740714 @default.
• W3046457130 creator A5054217898 @default.
• W3046457130 creator A5067261241 @default.
• W3046457130 creator A5070785437 @default.
• W3046457130 creator A5072058550 @default.
• W3046457130 creator A5089664974 @default.
• W3046457130 date "2020-11-01" @default.
• W3046457130 modified "2023-10-14" @default.
• W3046457130 title "Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation" @default.
• W3046457130 cites W1483664320 @default.
• W3046457130 cites W1564109452 @default.
• W3046457130 cites W1638197198 @default.
• W3046457130 cites W1925598703 @default.
• W3046457130 cites W1955863325 @default.
• W3046457130 cites W1973646541 @default.
• W3046457130 cites W1989307686 @default.
• W3046457130 cites W1989328007 @default.
• W3046457130 cites W1999443977 @default.
• W3046457130 cites W2008262167 @default.
• W3046457130 cites W2010732369 @default.
• W3046457130 cites W2035274512 @default.
• W3046457130 cites W2098274235 @default.
• W3046457130 cites W2110927467 @default.
• W3046457130 cites W2129747821 @default.
• W3046457130 cites W2142161841 @default.
• W3046457130 cites W2145095230 @default.
• W3046457130 cites W2152253814 @default.
• W3046457130 cites W2158188228 @default.
• W3046457130 cites W2168046861 @default.
• W3046457130 cites W2169086958 @default.
• W3046457130 cites W2222815228 @default.
• W3046457130 cites W2334676060 @default.
• W3046457130 cites W2343060625 @default.
• W3046457130 cites W2497639781 @default.
• W3046457130 cites W2572190179 @default.
• W3046457130 cites W2591348853 @default.
• W3046457130 cites W2771598353 @default.
• W3046457130 cites W2894630863 @default.
• W3046457130 cites W2899161153 @default.
• W3046457130 cites W2940427778 @default.
• W3046457130 cites W3005426886 @default.
• W3046457130 cites W3005616312 @default.
• W3046457130 doi "https://doi.org/10.1016/j.bbmt.2020.07.034" @default.
• W3046457130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32750422" @default.
• W3046457130 hasPublicationYear "2020" @default.
• W3046457130 type Work @default.
• W3046457130 sameAs 3046457130 @default.
• W3046457130 citedByCount "9" @default.
• W3046457130 countsByYear W30464571302021 @default.
• W3046457130 countsByYear W30464571302022 @default.
• W3046457130 countsByYear W30464571302023 @default.
• W3046457130 crossrefType "journal-article" @default.
• W3046457130 hasAuthorship W3046457130A5003501680 @default.
• W3046457130 hasAuthorship W3046457130A5015706959 @default.
• W3046457130 hasAuthorship W3046457130A5016144976 @default.
• W3046457130 hasAuthorship W3046457130A5053740714 @default.
• W3046457130 hasAuthorship W3046457130A5054217898 @default.
• W3046457130 hasAuthorship W3046457130A5067261241 @default.
• W3046457130 hasAuthorship W3046457130A5070785437 @default.
• W3046457130 hasAuthorship W3046457130A5072058550 @default.
• W3046457130 hasAuthorship W3046457130A5089664974 @default.
• W3046457130 hasBestOaLocation W30464571301 @default.
• W3046457130 hasConcept C10205521 @default.
• W3046457130 hasConcept C109159458 @default.
• W3046457130 hasConcept C126322002 @default.
• W3046457130 hasConcept C159047783 @default.
• W3046457130 hasConcept C159654299 @default.
• W3046457130 hasConcept C203014093 @default.
• W3046457130 hasConcept C2777408962 @default.
• W3046457130 hasConcept C28328180 @default.
• W3046457130 hasConcept C2911091166 @default.
• W3046457130 hasConcept C32611913 @default.
• W3046457130 hasConcept C54355233 @default.
• W3046457130 hasConcept C71924100 @default.
• W3046457130 hasConcept C86803240 @default.
• W3046457130 hasConceptScore W3046457130C10205521 @default.
• W3046457130 hasConceptScore W3046457130C109159458 @default.
• W3046457130 hasConceptScore W3046457130C126322002 @default.
• W3046457130 hasConceptScore W3046457130C159047783 @default.
• W3046457130 hasConceptScore W3046457130C159654299 @default.
• W3046457130 hasConceptScore W3046457130C203014093 @default.
• W3046457130 hasConceptScore W3046457130C2777408962 @default.
• W3046457130 hasConceptScore W3046457130C28328180 @default.
• W3046457130 hasConceptScore W3046457130C2911091166 @default.
• W3046457130 hasConceptScore W3046457130C32611913 @default.
• W3046457130 hasConceptScore W3046457130C54355233 @default.
• W3046457130 hasConceptScore W3046457130C71924100 @default.
• W3046457130 hasConceptScore W3046457130C86803240 @default.
• W3046457130 hasIssue "11" @default.
• W3046457130 hasLocation W30464571301 @default.
• W3046457130 hasOpenAccess W3046457130 @default.
• W3046457130 hasPrimaryLocation W30464571301 @default.
• W3046457130 hasRelatedWork W2046259286 @default.

• next